# Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Source: https://onco.cc/trials/nct02487459/  
OnCo record `nct02487459` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.

## Summary

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies is a phase 1 interventional study registered as NCT02487459 by Bellicum Pharmaceuticals, started 2016-07. Conditions recorded: Hematologic Malignancies. Interventions recorded: BPX-501 and AP1903.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02487459
- Phase: 1
- Setting: A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse
- Sponsor: Bellicum Pharmaceuticals

## Sources

- ClinicalTrials.gov NCT02487459: https://clinicaltrials.gov/study/NCT02487459

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Rivogenlecleucel](https://onco.cc/drugs/rivogenlecleucel/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct02487459.json